Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/27/2003WO2003024489A2 Combination of a nsaid and a pde-4 inhibitor
03/27/2003WO2003024488A2 Combination of a pde inhibitor and a leukotriene receptor antagonist
03/27/2003WO2003024487A1 Method of increasing the presence of glutathione in cells
03/27/2003WO2003024485A1 REMEDIES FOR DISEASES CAUSED BY β-AMYLOIDS CONTAINING 2-100β INHIBITOR AS THE ACTIVE INGREDIENT
03/27/2003WO2003024484A1 Remedies for pruritus
03/27/2003WO2003024483A1 Potentiator for inhibitory effects on urinary frequency and urinary incontinence
03/27/2003WO2003024481A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
03/27/2003WO2003024473A2 Retinoid receptor pan-antagonists for stimulating chondrogenesis
03/27/2003WO2003024472A2 Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
03/27/2003WO2003024460A1 Use of 7-alpha hydroxy dhea and 7-oxo dhea for treating inflammatory or functional intestinal diseases
03/27/2003WO2003024459A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
03/27/2003WO2003024458A1 Neuroprotection after traumatic brain injury
03/27/2003WO2003024457A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
03/27/2003WO2003024456A1 Methods for treating and preventing migraines
03/27/2003WO2003024455A2 Stent coated with a sustained-release drug delivery and method for use thereof
03/27/2003WO2003024454A2 Topical composition containing brucine and the use for the treatment of damaged mammalian skin
03/27/2003WO2003024453A1 Excitatory amino acid receptor antagonists
03/27/2003WO2003024452A1 Novel medicaments for inhalation
03/27/2003WO2003024450A1 Methods for treating prion diseases
03/27/2003WO2003024449A1 Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments
03/27/2003WO2003024448A2 Inhibitors of histone deacetylase
03/27/2003WO2003024446A1 Oxidation stress inhibitor and method of measuring oxidation stress
03/27/2003WO2003024445A1 Drugs comprising combination of antithrombotic agent with pyrazolone derivative
03/27/2003WO2003024444A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
03/27/2003WO2003024443A1 Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
03/27/2003WO2003024442A2 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003WO2003024441A1 Novel use of tricyclic compound
03/27/2003WO2003024440A1 Salicylic acid salts, methods for the production and use thereof as medicaments
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024438A1 Composition comprising cysteamine for improving lactation in dairy animals
03/27/2003WO2003024437A1 Allicin
03/27/2003WO2003024436A2 Method for treating skin disorders
03/27/2003WO2003024435A1 Immune modulation with polystyrene sulfonate
03/27/2003WO2003024434A2 Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage
03/27/2003WO2003024433A2 Compositions for treatment of common cold, comprising ipratropium and xylometazoline
03/27/2003WO2003024432A2 Device for transdermal administration for the treatment of urinary tract disorders
03/27/2003WO2003024431A1 Device for the administration of an active agent to the human skin
03/27/2003WO2003024426A1 Controlled release solid dispersions
03/27/2003WO2003024424A1 Stabilization of active agents by formulation into nanoparticulate form
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2003024422A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
03/27/2003WO2003024421A2 Triclosan dosage form
03/27/2003WO2003024420A1 Ophthalmic depot formulations for periocular or subconjunctival administration
03/27/2003WO2003024407A2 Inhibitors of rnase p proteins as antibacterial compounds
03/27/2003WO2003024405A2 Methods and compositions for inhibiting the proliferation of prostate cancer cells
03/27/2003WO2003024403A2 Carbohydrate supplementation and rehydration composition
03/27/2003WO2003024402A2 Lpa receptor agonists and antagonists and methods of use
03/27/2003WO2003024397A2 Enhancement of learning and memory and treatment of amnesia
03/27/2003WO2003024396A2 Dry powder medicament formulations
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024394A2 Method of treating benign prostatic hyperplasia and other beingn porstate conditions
03/27/2003WO2003024392A2 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003WO2003024391A2 Treatment and prevention of mucositis in cancer patients
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024388A2 Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
03/27/2003WO2003024386A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
03/27/2003WO2003024383A2 Methods and apparatus for improved administration of analgesics
03/27/2003WO2003024360A1 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003024298A2 Interspinous process implant sizer and distractor with a split head and size indicator and method
03/27/2003WO2003024246A1 Compositions for appetite control and related methods
03/27/2003WO2003024237A1 Oil composition
03/27/2003WO2003024223A1 Pesticidal formulations
03/27/2003WO2003024189A2 Method of modulating sodium ion absorption in epithelial cells
03/27/2003WO2003024183A2 Wortmannin analogs and methods of using same
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002149A3 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2003000220A3 Use of 1,2-decandiol for combating germs causing body odour
03/27/2003WO2002102311A3 Nanoparticles for treating targeted tissues and cells
03/27/2003WO2002100352A3 Nr2b receptor antagonists for the treatment or prevention of migraines
03/27/2003WO2002098854A3 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002096318A3 Method for treating glaucoma v
03/27/2003WO2002095050A3 Trinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094254A3 Abuse resistant pharmaceutical composition containing capsaicin
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002092003A3 Novel therapeutical quaternary ammonium compositions
03/27/2003WO2002091990A3 Prevention of addiction in pain management
03/27/2003WO2002089781A3 Methods of treating hyperlipidemia
03/27/2003WO2002078678A3 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
03/27/2003WO2002067987A3 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent
03/27/2003WO2002060879A3 Bacterial gyrase inhibitors and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002056941A3 Method for the treatment of peripheral vascular disease
03/27/2003WO2002054868A3 Pulmonary delivery of polyene antifungal agents
03/27/2003WO2002053190A3 Particles for inhalation having sustained release properties
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002053089A3 Stable skin conditioning compositions containing retinoid boosters
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002048147A3 Pyrazolopyridines
03/27/2003WO2002047680A3 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
03/27/2003WO2002043806A3 In vivo delivery methods and compositions
03/27/2003WO2002043738A3 Use of bisphosphonates for pain treatment
03/27/2003WO2002034727A3 Treatment of gastrointestinal stromal tumors
03/27/2003WO2002034201A3 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
03/27/2003WO2002032416A3 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
03/27/2003WO2002028381A3 Methods of inducing cancer cell death and tumor regression
1 ... 5520 5521 5522 5523 5524 5525 5526 5527 5528 5529 5530 5531 5532 5533 5534 5535 5536 5537 5538 5539 5540 ... 7860